Tal Michael G, Yevzlin Alexander S
Division of Interventional Radiology, Hadassah Medical Center, Jerusalem, Israel.
Department of Medicine, University of Michigan, Ann Arbor, MI, USA.
J Vasc Access. 2023 Jul;24(4):614-619. doi: 10.1177/11297298211027058. Epub 2021 Jul 21.
Tunneled hemodialysis catheter-related bloodstream infection is a major cause of morbidity and mortality in end-stage renal disease patients. Side holes positioned near the tip of catheters have been linked to formation of thrombi, which, in turn, have been implicated in predisposition to infection. In addition, side holes allow spillage of catheter locking solution, including antibiotics, thereby minimizing the lock solution's effect on the catheter tip. This study assessed the infection events that occurred in a series of hemodialysis patients using a non-side-hole catheter.
Over a period of 2 years, a novel symmetric-tip non-side-hole catheter was placed in 60 patients. Hemodialysis was performed thrice weekly. Prescribed dialyzer flows were 300-350 mL/min. Catheters were routinely locked with heparin 5000 units/mL between treatments. Patients were followed up for any catheter related complications, specifically infection events.
Seven events of catheter-related bloodstream infection occurred for a rate of 0.76 events per 1000 catheter-days, with the first event occurring 9 weeks after insertion. These events were treated by locking the affected catheter with 2 g of clindamycin in 2 mL of heparin 1000 units/mL and administration of intravenous antibiotics, in most cases, for 7-14 days. Two catheters were removed due to infection.
Catheter-related bloodstream infections with non-side-hole hemodialysis catheters do occur at a relatively low rate and in this initial preliminary study it seems that most of these infections can be successfully treated without removal of the affected catheters.
隧道式血液透析导管相关血流感染是终末期肾病患者发病和死亡的主要原因。位于导管尖端附近的侧孔与血栓形成有关,而血栓又与感染易感性有关。此外,侧孔会导致包括抗生素在内的导管封管液溢出,从而降低封管液对导管尖端的作用。本研究评估了一系列使用无侧孔导管的血液透析患者发生的感染事件。
在2年的时间里,为60例患者置入了一种新型对称尖端无侧孔导管。每周进行3次血液透析。规定的透析器血流量为300 - 350毫升/分钟。治疗期间,导管常规用5000单位/毫升的肝素封管。对患者进行随访,观察任何与导管相关的并发症,特别是感染事件。
发生了7例导管相关血流感染事件,发生率为每1000导管日0.76例,第一例事件发生在置管后9周。这些事件通过用2毫升含1000单位/毫升肝素的2克克林霉素封管受感染的导管并给予静脉抗生素治疗,大多数情况下治疗7 - 14天。2根导管因感染被拔除。
无侧孔血液透析导管相关血流感染确实以相对较低的发生率发生,在这项初步研究中,似乎大多数此类感染无需拔除受感染导管即可成功治疗。